title: Proteinuria, not altered albumin metabolism, affects hyperlipidemia in the nephrotic rat.
abstract: It has been established previously that nephrotic hyperlipidemia is characterized by both an increase in lipid synthesis and a defect in removal of lipoproteins. The relationship between these defects and altered albumin metabolism is uncertain. One hypothesis is that hepatic lipogenesis increases in parallel with albumin synthesis. To test this hypothesis, albumin synthesis was increased in nephrotic rats fed an 8.5% protein diet (LPN) by increasing dietary protein to 40% (HPN). Proteinuria was modulated in half of the rats fed 40% protein by enalapril (HPE). Albumin synthesis was the same in both HPN and HPE, but proteinuria was reduced in HPE compared to HPN, and so were serum cholesterol and triglycerides (TG). To examine the effect of serum albumin on lipid clearance in the absence of proteinuria, plasma clearance of chylomicrons (CM) and VLDL was measured in Nagase analbuminemic rats (NAR) and found to be no different than in normal SD rats. When proteinuria was induced in NAR and in SD rats, a severe and identical defect in both CM and VLDL clearance was acquired in both groups and blood lipid levels were increased to a similar degree in both groups. Neither hyperlipidemia nor defective removal of lipoproteins from the circulation are linked to albumin synthesis or serum albumin concentration but result, at least in part, from proteinuria. Postheparin lipoprotein lipase (LPL) activity was reduced slightly in nephrotic animals compared to nonnephrotic controls, but the most striking finding was a highly significant decrease in postheraprin LPL activity in normal NAR compared to SD rats (P less than 0.001), suggesting that reduced LPL activity is not responsible for reduced clearance of CM and VLDL in nephrotic rats.
authors.affiliation: Department of Medicine, Veteran's Administration Medical Center, Martinez, California 94553.
authors.forename: R W
authors.initials: RW
authors.lastname: Davies
authors.forename: I
authors.initials: I
authors.lastname: Staprans
authors.forename: F N
authors.initials: FN
authors.lastname: Hutchison
authors.forename: G A
authors.initials: GA
authors.lastname: Kaysen
mesh_terms: D000418:Albumins / Q000378:metabolism*; D000818:Animals; D002914:Chylomicrons / Q000378:metabolism; D004044:Dietary Proteins / Q000378:metabolism; D004656:Enalapril / Q000494:pharmacology; D006949:Hyperlipidemias / Q000503:physiopathology*; D008079:Lipoproteins, VLDL / Q000378:metabolism; D008657:Metabolic Clearance Rate; D009404:Nephrotic Syndrome / Q000503:physiopathology* / Q000652:urine; D011507:Proteinuria / Q000503:physiopathology*; D051381:Rats; D011919:Rats, Inbred Strains
chemical_list: D000418:Albumins; D002914:Chylomicrons; D004044:Dietary Proteins; D008079:Lipoproteins, VLDL; D004656:Enalapril